Veriskin is at the forefront of the most accurate skin cancer screening technology. Here you can find out what the company is up to.
Press Release
Veriskin Closes Seed-I Round
Effective date:
Veriskin, Inc. has completed closing of oversubscribed Series Seed-1 Preferred Equity Round led by Pasadena Angels and Ariel South East Angel Partners with participation of DigiLife Fund, Frontier Angels, Pasadena Angels Funds I and II, TiE SoCal Angels, Arizona Tech Investors and South Coast Angels.
Veriskin Receives Additional Funding From the NIH
Effective date:
Veriskin, Inc. has been awarded a $3M grant by the National Institutes of Health to further test its novel technology for non-invasive skin cancer screening. The National Cancer Institute that issued the award noted “the high significance of the clinical problem
being addressed, the sound rationale for the proposed work, overall innovation, the supportive
preliminary data, and the well-designed clinical trial”.
Veriskin Ranked Most Fundable Company by Pepperdine Graziadio Business School
Effective date:
Veriskin, Inc. is thrilled to announce that it achieved recognition on the Pepperdine Graziadio Business School’s fourth annual Most Fundable Companies® List. Veriskin competed against over 3,300 of early-stage US companies to be named one of 16 companies in total. The Most Fundable Companies initiative aims to educate founders on the investor diligence process and recognize exceptional entrepreneurs who are solving today’s problems with inventive solutions and are also seeking investment capital to fuel their company's growth.
Veriskin Initiates 3rd Clinical Study
Effective date:
Veriskin, Inc. has initiated a 1,000+ patient data collection clinical study for further development and testing of the TruScore device. The IRB approved study is conducted at 8 clinical sites in CA, OR, FL, NE and GA.
A Key Patent Granted in the US
Effective date:
The United States Patent and Trademark Office has approved Veriskin's application for a key patent that covers its core technology: US 11,089,969.
Veriskin Wins the 5th Annual Glendale Tech Week Pitchfest Competition
Effective date:
Pitchfest is one of many events lined up for the City of Glendale’s fifth annual Glendale Tech Week. Veriskin has won a prize package of $150,000.
Veriskin Raises Additional Capital for Seed-1 Round
Effective date:
Veriskin has completed a 2nd closing of the ongoing Seed-I round. Participating investors include Frontier Angels and TIE SoCal Angels.
Veriskin Opens Seed-I round
Effective date:
Veriskin, Inc. has completed initial closing of Series Seed-1 Preferred Equity Round led by Pasadena Angels and Ariel South East Angel Partners with participation of Pasadena Angels Fund 1.
FDA Recognizes the Novelty of Veriskin's Skin Cancer Detection Technology
Effective date:
FDA grants a Breakthrough Device Designation Status to the TruScore device. The FDA's Breakthrough Device Program is intended to expedite the development and prioritize the review of certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
Veriskin Selected as Connect 2020 Cool Company. Joins a Group of San Diego’s 30 Top-Performing Life Sciences Startups
Effective date:
Cool Companies is an annual capital program designed to match San Diego’s best technology and life sciences startups ready to raise Series A — with quality venture capital. The program selects top tier, local entrepreneurs raising institutional funding, and grants them opportunities for direct access to capital providers. The program regularly attracts over 200 VCs to the region annually. Since 2016, Cool Companies have raised over $400M, in just Series A institutional funding. Cool Companies 2020.
Veriskin Receives Funding Support from the NIH
Effective date:
Veriskin, Inc. has received a second $2M grant award from the National Cancer Institute. The NIH review panel cited an “outstanding application”, a “strong scientific premise” and was “highly enthusiastic” about the team. The funding will enable further development and clinical testing of the TruScore device.
A Key Patent Granted in Australia
Effective date:
IP Australia has approved Veriskin's application for a key patent that covers its core technology: TruScore Patent.
Veriskin Receives Special Invitation to LA BioMed Innovation Showcase 2018
Veriskin, Inc. has initiated a 100+ human clinical study to test the TruScore device. The IRB approved study is conducted by Palo Alto Medical Foundation (a division of Sutter Health).
Veriskin Invited to Present at TedX San Diego Innovation Alley
Effective date:
Veriskin, Inc. was invited to present at TedXs' Innovation Alley held in downtown San Diego that showecased 20 of San Diego’s most innovative companies and entrepreneurs. See event photos here.
Veriskin Receives NIH Grant to Pursue Skin Cancer Screening Technology
Effective date:
Veriskin, Inc. has been awarded a $1.875M grant by the National Institutes of Health to develop a novel technology for non-invasive skin cancer screening. The National Cancer Institute that issued the award cited “the exceptionally high impact that the proposed device is expected to make in the field of non-invasive skin cancer diagnostics”.
